Pear Therapeutics, Inc.

Thimble Point Acquisition Corp (Nasdaq: THMA), sponsored by Thimble Point LLC, completed its SPAC initial public offering in March 2021 targeting the healthcare and digital therapeutics sector. In June 2021, the blank-check company filed an 8-K announcing a definitive merger agreement with Pear Therapeutics, Inc., a Boston-based developer of prescription digital therapeutics for central nervous system disorders including substance use disorder, insomnia, and schizophrenia. The de-SPAC transaction closed in December 2022, with the combined company trading under the Pear Therapeutics name. Pear subsequently filed for Chapter 11 bankruptcy protection in January 2023. Visit SpacDesk and sign up for full filings, timeline data, and deal analytics on THMA and hundreds of other SPAC transactions.